Difference between revisions of "José Baselga"
(COVID-19/Premature death (stub for now, database problems)) |
m (Text replacement - "He served as " to "He was ") |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{person | {{person | ||
|wikipedia=https://en.wikipedia.org/wiki/Jos%C3%A9_Baselga | |wikipedia=https://en.wikipedia.org/wiki/Jos%C3%A9_Baselga | ||
| − | | | + | |interests=cancer |
| − | |description=Chief | + | |description=Chief cancer researcher at [[AstraZeneca]] dies at 61 of [[Creutzfeldt-Jakob disease]], possibly an effect of the [[Covid jab]]. |
|image=Jose baselga.jpg | |image=Jose baselga.jpg | ||
|nationality=Spanish | |nationality=Spanish | ||
|birth_date=3 July, 1959 | |birth_date=3 July, 1959 | ||
| − | |birth_place= | + | |birth_place=Barcelona,Catalonia,Spain |
|death_date=March 21, 2021 | |death_date=March 21, 2021 | ||
|death_place= | |death_place= | ||
|death_cause=Creutzfeldt-Jakob disease | |death_cause=Creutzfeldt-Jakob disease | ||
| − | |constitutes=scientist,bureaucrat,COVID-19/Premature death | + | |constitutes=scientist, bureaucrat, COVID-19/Premature death? |
}} | }} | ||
| − | '''Josep Baselga i Torres''', known in Spanish as '''José Baselga''' was a | + | '''Josep Baselga i Torres''', known in Spanish as '''José Baselga''' was a key figure in the study of [[oncology]] (cancer research) in [[Spain]] since the [[1990s]]. On January 7, 2019, [[AstraZeneca]] announced that they had hired him as head of research and development in [[oncology]], where he worked until his death of [[Creutzfeldt-Jakob disease]], possibly an effect of the [[Covid jab]]. |
| + | |||
| + | == Career == | ||
| + | Baselga started his career with the [[Memorial Sloan Kettering Cancer Center]] where he worked with [[John Mendelsohn (doctor)|John Mendelsohn]] in studying the role of [[Monoclonal antibody|monoclonal antibodies]] in the targeting proteins associated with breast and lung cancers.<ref name=":1" >https://www.nytimes.com/2021/03/25/health/dr-jose-baselga-dead.html</ref> He then returned to Spain, where he established the [[Vall d'Hebron University Hospital|Vall d'Hebron Institute of Oncology]] in Barcelona, within the [[Vall d'Hebron University Hospital]]. He was the chairman of the center from 1996 and 2010. During his time there, the institute emerged as a leading center of cancer research, therapies, and early stage clinical trials.<ref name=":1" /> Returning to the United States, he served at the [[Massachusetts General Hospital]] as the chief of its [[hematology]] and [[oncology]] divisions between 2010 and 2013.<ref name=":1" /> He then returned to the Memorial Sloan Kettering Cancer Center to become its chief medical officer in 2013.<ref name=":1" /> | ||
| + | |||
| + | He was appointed physician-in-chief at Memorial Sloan Kettering Cancer Center in 2012,<ref>http://www.healio.com/hematology-oncology/practice-management/news/print/hemonc-today/%7B20593db8-bd40-4c49-970a-9fe52a576835%7D/center-names-physician-in-chief</ref> and a professor of medicine at [[Weill Cornell Medical College]] in 2013.<ref>http://vivo.med.cornell.edu/display/cwid-job2078</ref> He held other leadership positions including serving as the president at the [[American Association for Cancer Research]] and was the editor of the ''[[Cancer Discovery]]'' medical journal.<ref name=":1" /> | ||
| + | |||
| + | He resigned from Memorial Sloan Kettering Cancer Center in September 2018, after an exposé by ''[[The New York Times]]'' and the non-profit investigative journalism organization [[ProPublica]], which called out that he had failed to report payments to the tune of millions of dollars from healthcare and drug companies in publications including [[The New England Journal of Medicine|''The'' ''New England Journal of Medicine'']] and ''[[The Lancet]]''.<ref>https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html?rref=collection%2Fsectioncollection%2Fscience</ref><ref>https://www.nytimes.com/2018/09/09/health/cancer-memorial-sloan-kettering-disclosure.html</ref> The incident led to the center announcing a rehaul of their [[conflict of interest]] policies. ''The New York Times'' also reported that the hospital paid more than $1.5 million in severance to Baselga in 2018 and 2019.<ref>https://www.nytimes.com/2020/12/22/health/memorial-sloan-kettering-cancer-center-doctor-jose-baselga.html?action=click&algo=bandit-all-surfaces-30min&block=trending_recirc&fellback=false&imp_id=223413925&impression_id=daed3487-44b5-11eb-91c3-dbc43a141c55&index=7&pgtype=Article®ion=footer&req_id=745109685&surface=most-popular&variant=3_bandit-all-surfaces-30min_daysback_4</ref> Baselga also resigned from the boards of the drug company [[Bristol Myers Squibb]] and the radiation equipment firm [[Varian Medical Systems]].<ref name=":0">https://www.nytimes.com/2019/01/07/health/baselga-sloan-kettering-astrazeneca.html?action=click&module=Latest&pgtype=Homepage</ref> He also resigned from his position as co-editor in chief of the journal ''[[Cancer Discovery]]''.<ref name=":0" /> | ||
| + | |||
| + | In January 2019, [[AstraZeneca]] announced that they had hired Baselga as head of research and development in oncology, where he worked until his death.<ref name=":0" /> During this time, he led the company's partnership with Japanese pharmaceutical company [[Daiichi Sankyo]], to develop two cancer treatments in addition to building the company's cancer research capabilities.<ref name=":1" /> | ||
| + | |||
| + | He was based in Gaithesburg, [[Maryland]], in the Washington metropolitan area. Since the beginning of [[Covid]], he had refocused part of his research to developing Covid therapies based on his cancer experience.<ref name=vanguardia>https://www.lavanguardia.com/ciencia/20210321/6603446/josep-baselga-muere.html</ref> | ||
| + | |||
| + | In his last public appearance, on November 2, [[2020]], he predicted that "before the end of the year there will already be more than one vaccine available." <ref name=vanguardia/> | ||
| + | |||
| + | ==Death== | ||
| + | Baselga died at the age of 61, a victim of [[Creutzfeldt-Jakob disease]], a rapidly evolving degenerative neurological disorder.<ref name=vanguardia/> | ||
| + | |||
| + | |||
{{SMWDocs}} | {{SMWDocs}} | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
| − | {{ | + | {{PageCredit |
| + | |site=Wikipedia | ||
| + | |date=04.04.2022 | ||
| + | |url=https://en.wikipedia.org/wiki/Jos%C3%A9_Baselga | ||
| + | }} | ||
Latest revision as of 14:09, 6 June 2023
 José Baselga    (scientist, bureaucrat, COVID-19/Premature death?) | |
|---|---|
 | |
| Born | 3 July, 1959 Barcelona, Catalonia, Spain |
| Died | March 21, 2021 (Age 61) |
Cause of death | Creutzfeldt-Jakob disease |
| Nationality | Spanish |
| Interests | cancer |
Chief cancer researcher at AstraZeneca dies at 61 of Creutzfeldt-Jakob disease, possibly an effect of the Covid jab. | |
Josep Baselga i Torres, known in Spanish as José Baselga was a key figure in the study of oncology (cancer research) in Spain since the 1990s. On January 7, 2019, AstraZeneca announced that they had hired him as head of research and development in oncology, where he worked until his death of Creutzfeldt-Jakob disease, possibly an effect of the Covid jab.
Career
Baselga started his career with the Memorial Sloan Kettering Cancer Center where he worked with John Mendelsohn in studying the role of monoclonal antibodies in the targeting proteins associated with breast and lung cancers.[1] He then returned to Spain, where he established the Vall d'Hebron Institute of Oncology in Barcelona, within the Vall d'Hebron University Hospital. He was the chairman of the center from 1996 and 2010. During his time there, the institute emerged as a leading center of cancer research, therapies, and early stage clinical trials.[1] Returning to the United States, he served at the Massachusetts General Hospital as the chief of its hematology and oncology divisions between 2010 and 2013.[1] He then returned to the Memorial Sloan Kettering Cancer Center to become its chief medical officer in 2013.[1]
He was appointed physician-in-chief at Memorial Sloan Kettering Cancer Center in 2012,[2] and a professor of medicine at Weill Cornell Medical College in 2013.[3] He held other leadership positions including serving as the president at the American Association for Cancer Research and was the editor of the Cancer Discovery medical journal.[1]
He resigned from Memorial Sloan Kettering Cancer Center in September 2018, after an exposé by The New York Times and the non-profit investigative journalism organization ProPublica, which called out that he had failed to report payments to the tune of millions of dollars from healthcare and drug companies in publications including The New England Journal of Medicine and The Lancet.[4][5] The incident led to the center announcing a rehaul of their conflict of interest policies. The New York Times also reported that the hospital paid more than $1.5 million in severance to Baselga in 2018 and 2019.[6] Baselga also resigned from the boards of the drug company Bristol Myers Squibb and the radiation equipment firm Varian Medical Systems.[7] He also resigned from his position as co-editor in chief of the journal Cancer Discovery.[7]
In January 2019, AstraZeneca announced that they had hired Baselga as head of research and development in oncology, where he worked until his death.[7] During this time, he led the company's partnership with Japanese pharmaceutical company Daiichi Sankyo, to develop two cancer treatments in addition to building the company's cancer research capabilities.[1]
He was based in Gaithesburg, Maryland, in the Washington metropolitan area. Since the beginning of Covid, he had refocused part of his research to developing Covid therapies based on his cancer experience.[8]
In his last public appearance, on November 2, 2020, he predicted that "before the end of the year there will already be more than one vaccine available." [8]
Death
Baselga died at the age of 61, a victim of Creutzfeldt-Jakob disease, a rapidly evolving degenerative neurological disorder.[8]
Event Participated in
| Event | Start | End | Location(s) | Description |
|---|---|---|---|---|
| WEF/Annual Meeting/2016 | 20 January 2016 | 23 January 2016 | Switzerland World Economic Forum | Attended by over 2500 people, both leaders and followers, who were explained how the Fourth Industrial Revolution would changed everything, including being a "revolution of values". |
References
- ↑ a b c d e f https://www.nytimes.com/2021/03/25/health/dr-jose-baselga-dead.html
- ↑ http://www.healio.com/hematology-oncology/practice-management/news/print/hemonc-today/%7B20593db8-bd40-4c49-970a-9fe52a576835%7D/center-names-physician-in-chief
- ↑ http://vivo.med.cornell.edu/display/cwid-job2078
- ↑ https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html?rref=collection%2Fsectioncollection%2Fscience
- ↑ https://www.nytimes.com/2018/09/09/health/cancer-memorial-sloan-kettering-disclosure.html
- ↑ https://www.nytimes.com/2020/12/22/health/memorial-sloan-kettering-cancer-center-doctor-jose-baselga.html?action=click&algo=bandit-all-surfaces-30min&block=trending_recirc&fellback=false&imp_id=223413925&impression_id=daed3487-44b5-11eb-91c3-dbc43a141c55&index=7&pgtype=Article®ion=footer&req_id=745109685&surface=most-popular&variant=3_bandit-all-surfaces-30min_daysback_4
- ↑ a b c https://www.nytimes.com/2019/01/07/health/baselga-sloan-kettering-astrazeneca.html?action=click&module=Latest&pgtype=Homepage
- ↑ a b c https://www.lavanguardia.com/ciencia/20210321/6603446/josep-baselga-muere.html
This page imported content from Wikipedia on 04.04.2022.Wikipedia is not affiliated with Wikispooks. Original page source here
